Results 251 to 260 of about 51,902 (295)

Emerging role of Janus kinase inhibitors in ulcerative colitis management. [PDF]

open access: yesWorld J Gastrointest Pharmacol Ther
Ahsan MU   +5 more
europepmc   +1 more source

Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Albert Wolkerstorfer   +10 more
wiley   +1 more source

Janus kinases in immune cell signaling [PDF]

open access: yesImmunological Reviews, 2009
Summary:  The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non‐receptor protein tyrosine kinases. They are involved in cell growth, survival, development, and differentiation of a variety of cells but are critically important for immune cells and hematopoietic cells.
Kamran Ghoreschi   +2 more
exaly   +3 more sources

Negative Regulation of Janus Kinases

Cell Biochemistry and Biophysics, 2001
The precise regulation of both the magnitude and the duration of Janus kinase (JAK) catalytic activity is essential for the cytokine orchestration of many biological processes, and the dysregulation of JAK activity has pathological implications.
R J, Duhé, L H, Wang, W L, Farrar
openaire   +2 more sources

Malignancy and Janus Kinase Inhibition

Rheumatic Disease Clinics of North America, 2017
The use of biologics such as anti-tumor necrosis factor and oral Janus kinase inhibitors have revolutionized the treatment of rheumatoid arthritis (RA). The risk of malignancies such as lymphomas, lung cancer, and nonmelanoma skin cancers (NMSCs) is greater in patients with RA compared with the general population.
Padmapriya, Sivaraman, Stanley B, Cohen
openaire   +2 more sources

The many faces of Janus kinase

Biochemical Pharmacology, 2012
Janus kinases have proved to be essential for many immunological processes but there is growing evidence that they also play a critical role in pathogenesis of many diseases including inflammatory diseases and cancer where they promote multiple steps of tumorigenesis.
Matthew M, Seavey, Pawel, Dobrzanski
openaire   +2 more sources

Janus Kinase Mutations

Seminars in Oncology, 2009
The chronic myeloproliferative neoplasms (MPNs) polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF) are commonly associated with mutations in the Janus kinase gene JAK2. A hallmark of PV is an abundance of red blood cells; ET, too many platelets; and MF, accumulation of neutrophils and monocytes accompanied by bone ...
openaire   +2 more sources

Janus kinases in cytokine signalling

Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences, 1996
Abstract Hematopoiesis is largely regulated by the binding of cytokines to receptors of the cytokine receptor superfamily. Although lacking catalytic domains, members of the cytokine receptor superfamily mediate ligand dependent activation of tyrosine phosphorylation which is critical for all receptor functions.
James N. Ihle, Christopher John Marshall
openaire   +2 more sources

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Mapping the kinase domain of janus kinase 3

Bioorganic & Medicinal Chemistry Letters, 2003
The utilization and impact of parallel synthesis on lead exploration around initial hit oxindole (1) are described. The emergent SAR, analogue design and functional impact will also be detailed.
Christopher, Adams   +24 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy